Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E6.97 EPS (ttm)11.35 Insider Own0.40% Shs Outstand1.32B Perf Week-2.77%
Market Cap104.41B Forward P/E6.81 EPS next Y11.62 Insider Trans-19.87% Shs Float1.31B Perf Month1.56%
Income16.35B PEG- EPS next Q2.88 Inst Own80.50% Short Float1.23% Perf Quarter-6.20%
Sales32.37B P/S3.23 EPS this Y62.00% Inst Trans-2.77% Short Ratio1.54 Perf Half Y-15.06%
Book/sh11.64 P/B6.80 EPS next Y-1.17% ROA32.70% Target Price104.50 Perf Year-17.80%
Cash/sh6.63 P/C11.93 EPS next 5Y-0.21% ROE100.80% 52W Range76.21 - 108.83 Perf YTD-20.51%
Dividend1.88 P/FCF7.18 EPS past 5Y48.30% ROI45.90% 52W High-27.30% Beta1.10
Dividend %2.38% Quick Ratio1.60 Sales past 5Y32.60% Gross Margin87.10% 52W Low3.82% ATR1.38
Employees8000 Current Ratio1.80 Sales Q/Q-5.70% Oper. Margin63.00% RSI (14)49.22 Volatility1.69% 1.59%
OptionableYes Debt/Eq1.42 EPS Q/Q-11.50% Profit Margin50.50% Rel Volume1.05 Prev Close77.86
ShortableYes LT Debt/Eq1.38 EarningsOct 25 AMC Payout15.20% Avg Volume10.48M Price79.12
Recom2.20 SMA200.28% SMA50-0.73% SMA200-8.75% Volume10,997,392 Change1.62%
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-03-16Reiterated Oppenheimer Outperform $124 → $120
Feb-03-16Reiterated Barclays Overweight $130 → $115
Feb-03-16Initiated Standpoint Research Buy $110
Jan-20-16Initiated Credit Suisse Outperform $125
Jan-15-16Upgrade BofA/Merrill Underperform → Neutral $107
Oct-28-15Reiterated Maxim Group Buy $129 → $137
Oct-01-16 12:13PM  Hey Gilead, It's Time to Start Looking Over Your Shoulder in Hepatitis C at Motley Fool
Sep-30-16 06:03PM  Could Growing HIV Franchise Drive Gilead Sciences Valuation?
04:48PM  Regeneron Pharmaceuticals Falls As Combo Therapy Worse Than Eylea Alone
03:04PM  Cempra Gets More Good News
12:42PM  [$$] Gilead's Growth Tonic Is Elusive, May Have Side Effects at The Wall Street Journal
12:07PM  Gilead Sciences (GILD) Stock Climbs, Citi: Hepatitis C Sales to Improve
11:52AM  Buy These 4 Stocks and Beat Biotech's Slump
10:56AM  Two Big Biotechs Flash Bearish Signals at Investopedia
10:06AM  Gilead Sciences: Are Hepatitis C Sales Improving? at Barrons.com
Sep-29-16 04:26PM  Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure
Sep-28-16 11:20PM  Gilead May Not Acquire Galapagos, For Now (GILD, GLPG) at Investopedia
02:26PM  Gilead Sciences Stock Downgraded: 3 Things You Need to Know at Motley Fool
12:25PM  Four Stellar Stocks to Beat the Biotech Slump at TheStreet
Sep-27-16 05:59PM  Final Trade: BAC, GILD & more
05:41PM  Blockbuster biotech deal coming?
04:28PM  Gilead 'Paralyzed' On Likely Hepatitis C Share Loss To AbbVie, Merck
04:05PM  Gilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration Business Wire
03:02PM  Why Cash Is King for Biotech Stocks at Motley Fool
02:41PM  Street Talk: GILD & AZO
12:42PM  Why Wells Fargo, Gilead, Newfield, Amgen, and Chesapeake Energy Are Trending at Insider Monkey
11:23AM  The Drug Price Increase Debate: Separating The Winners From The Losers
10:39AM  Jim Cramer -- Gilead Needs to Make an Acquisition
10:00AM  Gilead Sciences: Tired of Waiting at Barrons.com
09:54AM  Cramer's Stop Trading: GILD, GWPH & ALKS
08:14AM  Gilead (GILD) Stock Falls on Ratings Downgrade
08:08AM  Analysts' Actions -- AutoZone, Eli Lilly, J.M. Smucker, Toll Brothers and More
07:50AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
07:05AM  5 Safe Stocks to Buy Today at Motley Fool
06:28AM  Gilead Sciences downgraded by Leerink Partners
Sep-26-16 04:03PM  Wall Street Sells Off on Worries Over Clinton-Trump Showdown
02:46PM  Who's Doing What To Whom In The Back Seat Of The Car? at Forbes
02:38PM  Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
02:29PM  Will Gilead (GILD) Stock Be Helped by Positive Crohn's Drug Results?
11:04AM  Whats the Upside Potential for Gilead?
10:46AM  Gilead Sciences: A 'Slight Uplift' for R&D Strategy? at Barrons.com
10:05AM  Gileads TAF-Based Regimen Should Drive HIV Franchise Revenue
08:06AM  How Gilead Dominates the HCV Space
Sep-24-16 09:24AM  7 Best Roth IRA Stocks for 2017 at Motley Fool
Sep-23-16 07:01PM  Cramer: Here Are the Reasons the Market Is Hated
03:04PM  Population Dynamics for Gileads HCV Products
01:04PM  Why Analysts Expect Gileads Revenue to Fall in 2016 and 2017
11:38AM  Top 5 profitable Biotech stocks : September 23, 2016
11:10AM  The Factors behind Gileads Discounted Valuation
10:44AM  Gilead (GILD) Stock Higher, Citigroup: Hepatitis C Drug Sales Improving
10:04AM  What Are Analysts Recommendations for Gilead Sciences?
09:36AM  Gilead Sciences: Are Hepatitis C Sales Getting Better? at Barrons.com
09:07AM  The Cheapest Stocks in Biotech at Motley Fool
08:08AM  Gilead Sciences Focuses on a Strong Inorganic Growth Strategy
07:20AM  Why Is Gilead Sciences Trading at a Cheap Valuation?
07:20AM  Gilead Sciences: High Gross Margins despite Weak Sales
07:20AM  Analyzing Gilead Sciences Stock Performance
Sep-22-16 05:59PM  Final Trade: GILD, TWTR & more
05:42PM  Gilead diving into M&A?
04:35PM  Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle
04:20PM  Gilead Sciences Inc.'s Biggest Win in 2016 So Far at Motley Fool
04:07PM  Will Gilead Make a Good Fit for Allergan? (GILD) at Investopedia
03:11PM  Gilead Ends Bowel Disease Treatment Trials (GILD) at Investopedia
11:53AM  Gilead Sciences: Another Blow to R&D Strategy at Barrons.com
11:51AM  Gilead Sciences, Inc. Value Analysis (NASDAQ:GILD) : September 22, 2016
11:20AM  Gilead Sciences (GILD) Stock Lower Despite Bullish Gabelli Note
10:48AM  The Pros and Cons of Buying Gilead Sciences Stock at Motley Fool
10:32AM  Gilead Sciences: A Hidden Asset? at Barrons.com
10:26AM  Allergan is Not Going to Buy Gilead at Bloomberg
08:04AM  Moves in Cancer Therapeutics among Recent Developments for Ionis
07:51AM  Gilead to Stop GS-5745 Development for Ulcerative Colitis
05:53AM  Is Galectin The Next Takeover Target for the Biotech World?
Sep-21-16 05:00PM  Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis Business Wire
03:16PM  Biotech: Why NASH is So Hot Right Now at Barrons.com
10:37AM  Gilead Sciences (GILD) Stock Lower, Gabelli: Allergan Could Be Buyer
10:30AM  Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers'
09:38AM  Gilead Sciences: Allergan's Next Target? at Barrons.com
08:08AM  Gilead Sciences, Inc. breached its 50 day moving average in a Bullish Manner : GILD-US : September 21, 2016
07:21AM  Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
12:00AM  Big Pharma, Biotech Attack NASH Liver Illness From All Sides at Bloomberg
Sep-20-16 08:14PM  Potential Acquisitions for Gilead Sciences (GILD) at Investopedia
05:09PM  GILEAD SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Ob
03:28PM  Biotech buyout: The next big liver disease
03:16PM  Here's a Reason Why Gilead (GILD) Stock Is Gaining Today
01:47PM  Gilead Is in Breakout Mode
01:30PM  This Hated Pharma Stock Has A Bright Future
12:09PM  The 5 Top-Selling Drugs In The World
12:00PM  Gilead Sciences: Why Allergan's Tobira Purchase is Wonderful, Wonderful News at Barrons.com
07:16AM  How Safe Is Gilead Sciences Inc. and Its Dividend? at Motley Fool
Sep-19-16 03:56PM  Hateful Paper: Washed Out, Worth A Shot at Forbes
03:00PM  After Losing Medivation, Who Is Gilead Going After Next? at Forbes
Sep-18-16 03:18PM  How Risky Is Gilead Sciences Inc.? at Motley Fool
Sep-17-16 02:27AM  [$$] Will Bayer's Takeover of Monsanto Be a Bust? at Barrons.com
Sep-16-16 04:15PM  Gilead Notes Issue to Close on Sept. 20 (GILD) at Investopedia
03:27PM  Gilead ready to shop?
03:00PM  You've Got the Brains, I've Got the Book, Let's Make Lots of Money
11:21AM  Gilead (GILD) Stock Down, Jefferies: $5 Billion Debt Offering Suggests 'Imminent' Deal
08:12AM  Are We Unprepared For Another Ebola Outbreak? at Forbes
Sep-15-16 10:01PM  Gilead Prices $5 Billion of Senior Unsecured Notes Business Wire
11:18AM  Gilead Sciences, Inc. -- Moody's rates Gilead's notes A3; stable outlook at Moody's
11:17AM  Gilead's Pipeline, Maligned by Investors, Still Packed With 4Q Clinical Trial Readouts
09:31AM  5 Stocks Expected to Outperform this Week According to Forcerank
09:30AM  The Zacks Analyst Blog Highlights: TOTAL, Oracle and Gilead Sciences
Sep-14-16 07:45PM  Gilead Remains Promising Despite Recent Declines (GILD) at Investopedia
02:44PM  Street Talk: GILD, FCX & more
02:33PM  Major Analyst Action Surrounding These Stocks Today at Insider Monkey
Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company's products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsMar 14Sale90.005,000450,000147,090Mar 15 07:31 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise16.40100,0001,639,5004,119,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Option Exercise16.40112,0001,836,2401,170,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Option Exercise24.912,00049,81063,122Mar 03 03:10 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Sale87.79112,0009,832,9951,058,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Sale87.902,000175,80061,122Mar 03 03:10 PM
MARTIN JOHN CChairman and CEOMar 01Sale88.58100,0008,857,8544,019,727Mar 03 02:47 PM
Washington Robin LEVP, CFOFeb 16Sale90.726,250567,00084,688Feb 18 07:59 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise16.40100,0001,639,5004,048,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Option Exercise39.142,00078,27150,783Feb 03 05:42 PM
MARTIN JOHN CChairman and CEOFeb 01Sale83.42100,0008,342,4753,948,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Sale82.322,000164,64048,783Feb 03 05:42 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Option Exercise25.762,00051,52650,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Option Exercise16.40100,0001,639,5004,048,066Jan 06 05:21 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Sale99.202,000198,40048,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Sale97.68100,0009,767,7083,948,066Jan 06 05:21 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Option Exercise21.9970,0001,539,562197,936Dec 17 03:40 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Sale102.4170,0007,168,741127,936Dec 17 03:40 PM
MILLIGAN JOHN FPresident and COODec 07Option Exercise14.50100,0001,450,2501,129,108Dec 09 02:14 PM
MILLIGAN JOHN FPresident and COODec 07Sale103.18100,00010,317,9771,029,108Dec 09 02:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.3010,000242,950141,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise26.992,00053,98050,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise14.50150,0002,175,3754,098,066Dec 03 01:57 PM
MARTIN JOHN CChairman and CEODec 01Sale105.82150,00015,873,4673,948,066Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale106.382,000212,76048,783Dec 03 01:56 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale106.0112,0001,272,159129,422Dec 03 01:57 PM
Cogan John FrancisDirectorNov 24Option Exercise20.7115,000310,57559,309Nov 25 02:21 PM
Cogan John FrancisDirectorNov 24Sale105.9515,0001,589,19044,309Nov 25 02:21 PM
Whitley Richard JamesDirectorNov 24Sale106.4816917,99530,719Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 23Sale107.182,863306,84530,888Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 20Sale106.995,514589,91733,751Nov 25 02:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Option Exercise23.7670,0001,662,850235,168Nov 18 12:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Sale102.6570,0007,185,419165,168Nov 18 12:32 PM
MILLIGAN JOHN FPresident and COONov 09Option Exercise14.50100,0001,450,2501,129,108Nov 12 01:01 PM
MILLIGAN JOHN FPresident and COONov 09Sale107.66100,00010,765,6441,029,108Nov 12 01:01 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000033,724Nov 09 05:41 PM
MARTIN JOHN CChairman and CEONov 02Option Exercise14.50150,0002,175,3754,098,066Nov 04 01:23 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Option Exercise24.3010,000242,950143,422Nov 04 02:41 PM
Carter Paul RutherfordEVP Commercial OpsNov 02Sale108.362,000216,71248,783Nov 04 04:27 PM
Washington Robin LEVP, CFONov 02Sale109.466,250684,15088,046Nov 04 04:21 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Sale109.3812,0001,312,507131,422Nov 04 02:41 PM
MARTIN JOHN CChairman and CEONov 02Sale109.42150,00016,413,0263,948,066Nov 04 01:23 PM
Cogan John FrancisDirectorOct 27Option Exercise20.7115,000310,57559,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 27Sale110.0015,0001,650,00044,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 26Option Exercise20.7115,000310,57559,309Oct 27 03:09 PM
Carter Paul RutherfordEVP Commercial OpsOct 26Sale110.061,500165,09248,783Oct 28 02:51 PM
Cogan John FrancisDirectorOct 26Sale110.0015,0001,650,00044,309Oct 27 03:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Option Exercise23.6070,0001,652,248235,168Oct 16 05:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Sale100.0570,0007,003,220165,168Oct 16 05:32 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise14.50100,0001,450,2501,129,108Oct 08 02:06 PM
MILLIGAN JOHN FPresident and COOOct 07Sale99.22100,0009,921,5241,029,108Oct 08 02:06 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Option Exercise24.305,000121,475138,422Oct 07 01:22 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Sale100.005,000500,000133,422Oct 07 01:22 PM